Effects of topical application of realgar on pruritus and inflammation of atopic dermatitis

Jae Sung Lee; You Yeon Choi; Woong Mo Yang; Lee, Jae Sung; Choi, You Yeon; Yang, Woong Mo

doi:10.13048/jkm.15002

JKM > Volume 36(1); 2015 > Article

Lee, Choi, and Yang: Effects of topical application of realgar on pruritus and inflammation of atopic dermatitis

Original Article

The Journal of Korean Oriental Medicine 2015; 36(1): 9-21.

DOI: https://doi.org/10.13048/jkm.15002

Effects of topical application of realgar on pruritus and inflammation of atopic dermatitis

Jae Sung Lee, You Yeon Choi, Woong Mo Yang

Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University

Correspondence to: 양웅모 (Woong Mo Yang), 서울시 동대문구 회기동 1번지 경희대학교 한의과대학, Tel: +82-2-961-2209, E-mail: wmyang@khu.ac.kr

Received December 03, 2014 Revised March 13, 2015 Accepted March 17, 2015

Abstract

Objectives:

Realgar has been frequently used for skin disorders in history of herbal medicine. However, the efficacy of realgar has not been examined in atopic dermatitis (AD). In this study, the effects of realgar on AD were investigated, especially on pruritus and inflammation.

Methods:

AD lesions were induced in the shaved backs of BALB/c mice through repeated application of DNCB. The mice were treated for 11 days with 1% realgar (100 μL/day). Histological changes in skin thickness were observed. The anti-pruritic effects of realgar were evaluated by the change in numbers of scratching behavior of mice and expression of substance P. The expressions of cytokines IL-4 and IL-6 were measured. Also, anti-inflammatory effects of realgar were examined on expressions of NF-κB, phospho-I κB α and mitogen-activated protein kinases (MAPKs).

Results:

Realgar decreased skin thickness (both dermal and epidermal) 38% and 17% respectively, compared to positive control, DNCB group. The scratching behavior of mice was reduced by 42% and expression of substance P was significantly less. Cytokines IL-4 and IL-6 were significantly reduced by 52.6% and 77.6%, respectively. The expressions of NF-κB, phospho-I κBα and MAPKs (phospho-ERK1/2, -p38 and -JNK) were significantly suppressed with marked effects on phospho-ERK1/2.

Conclusions:

The collective results suggest that realgar shows anti-pruritic and anti-inflammatory effects on AD. And realgar might be a potential therapeutic candidate for treatment of atopic dermatitis.

Keywords: Realgar, atopic dermatitis, scratching behavior, inflammation, pruritus

Fig. 1.

Experimental schedule. ▲: The shaved dorsal skin was applied with 100 µL of 1% DNCB solution (in acetone: olive oil=4:1) for sensitization, ●: The realgar group were treated 1% realgar (5 mg/day) and the DEX group treated 100 µL dexamethasone (10 uM, dissolved in PBS), △: 100 µL of 0.5 % DNCB solution were applied on the dorsal skin.

Fig. 2.

Change in epidermis and dermis upon application of realgar. (A) The thickness of epidermis, (B) The thickness of dermis. Hematoxylin-eosin staining showed a decrease thickness of epidermis and dermis in the realgar-treated group and DEX group. Results shown are representative of five observations. Data are presented as means ± SD and analyzed with ANOVA. ^###P < 0.001, versus the NOR group. ^***P < 0.001, versus the DNCB group. Magnification : X 100.

Fig. 3.

Changes in scratching behavior upon application of realgar. Scratching behavior of mouse was checked after 1 h had passed following the last application of DNCB (on 18 day). Each mouse of all group were videotaped for 20 min to count the number of scratching behavior. Data are presented as means ± SD (n = 5) and analyzed with ANOVA. ^###P < 0.001, versus the NOR group. ^**P < 0.05, versus the DNCB group.

Fig. 4.

Changes in substance P expression upon application of realgar. The expression of substance P was confirmed by Immunohistochemistry staining. Skin specimens were excised 12 h after the final DNCB challenge. The arrow indicates the expression of substance P. Magnification : X 200.

Fig. 5.

Changes in cytokine levels upon application of realgar. The cytokine levels of IL-4 and IL-6 were measured in the dorsal skin using mouse ELISA kits. Data are presented as means ± SD (n = 5) and analyzed with ANOVA.^###P < 0.001, versus the NOR group. ^***P < 0.001, versus the DNCB group.

Fig. 6.

Changes in expressions of NF-κB, phospho-IκBα upon application of realgar. The effects of realgar on the expressions of NF-κB and phospho-IκBα was assessed using western blot analysis. Results shown are representative of five observations. Data are presented as means ± SD and analyzed with ANOVA. ^###P < 0.001, versus the NOR group. ^***P < 0.001, ^**P < 0.01, versus the DNCB group.

Fig. 7.

Changes in MAPKs upon application of realgar. (A) phospho-ERK1/2, (B) phospho-p38 and (C) phospho-JNK. Total protein of the dorsal skin was analyzed by western blotting. Results shown are representative of five observations. Data are presented as means ± SD and analyzed with ANOVA. ^###P < 0.001, versus the NOR group. ^***P < 0.001, ^**P < 0.01, versus the DNCB group.

Fig. 8.

Changes in liver tissues upon application of realgar. Results shown are representative of five observations. Magnification: X 200.

참고문헌

1.. Bieber, T. Atopic dermatitis. N Engl J Med, (2008). 358, 1483-94.

2.. Akdis, CA, Akdis, M, Bieber, T, Bindslev-Jensen, C, Boguniewicz, M, & Eigenmann, P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol, (2006). 118(1), 152-169.

3.. DaVeiga, SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc, (2012). 33(3), 227-234.

4.. Ständer, S, & Luger, TA. Itch in atopic dermatitis–pathophysiology and treatment. Acta Dermatovenerol Croat, (2010). 18(4), 289-296.

5.. Klein, PA, & Clark, RAF. An Evidence-Based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol, (1999). 135(12), 1522-1525.

6.. Sher, L, Chang, J, Patel, B, Balkrishnan, R, & Fleischer, AB. Relieving the Pruritus of Atopic Dermatitis: A Meta-analysis. Value Health, (2012). 15(4), A249-A250.

7.. Sohn, KH, Lee, JG, & Jee, SY. A philological study on demonstration of atopic dermatitis. J East-West Med, (2009). 34(4), 15-24.

8.. Min, DL, Park, EJ, & Kang, KH. Review of Clinical and Experimental Studies on External Application Treatment for Atopic Dermatitis in the Korean Literature. J Pediatr Korean Med, (2013). 27(1), 36-49.

9.. Park, BK, Chang, GT, & Kim, JH. A study of external treatments for the atopic dermatitis. J Korean Orient Pediatr, (2003). 17(1), 71-86.

10.. Wu YL. Bonchojongsin. First edition. Seoul. Haeng Lim Publishers Co;(1982). p. 143

11.. Heo J. Newly translated Donguibogam. Second edition. Seoul. Bubin Publishers Co;(2009). p. 797-810.

12.. Lee, KS, Jeong, ES, Heo, SH, Seo, JH, Jeong, DG, & Choi, YK. A Novel Model for Human Atopic Dermatitis: Application of Repeated DNCB Patch in BALB/c Mice, in Comparison with NC/Nga Mice. Lab Anim, (2010). 26(1), 95-102.

13.. Kabashima, K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Invest Dermatol, (2013). 70, 3-11.

14.. Cork, MJ, Danby, SG, Vasilopoulos, Y, Hadgraft, J, Lane, ME, & Moustafa, M, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol, (2009). 129(8), 1892-1908.

15.. Ye, YM, Kim, BE, Shin, YS, Park, HS, & Leung, DYM. Overexpression of Epidermal Filaggrin in Patients with Chronic Idiopathic Urticaria Correlates with Urticaria Severity. J Allergy Clin Immunol, (2013). 131(2), AB56.

16.. Koblenzer, CS. Itching and the atopic skin. J Allergy Clin Immunol, (1999). 104(3), S109-S113.

17.. Gupta, MA, & Gupta, AK. Depression modulates pruritus perception. A study of pruritus in psoriasis, atopic dermatitis and chronic idiopathic urticaria. Ann N Y Acad Sci, (1999). 885, 394-395.

18.. Shim, WH, Song, CH, Park, HJ, Kim, HS, Chin, HW, & Kim, SH, et al. Clinical characteristics of itch in patients with adult and childhood atopic dermatitis. Korean J Dermatol, (2011). 49(4), 318-327.

19.. Park, SW, Yan, YP, Satriotomo, I, Vemuganti, R, & Dempsey, RJ. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J. Neurosurg, (2007). 107(3), 593-599.

20.. Donkin, JJ, Turner, RJ, Hassan, I, & Vink, R. Substance P in traumatic brain injury. Prog Brain Res, (2007). 161, 97-109.

21.. Ebner, K, & Singewald, N. The role of substance P in stress and anxiety responses. Amino Acids, (2006). 31(3), 251-272.

22.. Yamaoka, J, & Kawana, S. Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice. J Dermatol Sci, (2007). 48(2), 123-132.

23.. Hon, KLE, Lam, MCA, Wong, KY, Leung, TF, & Ng, PC. Pathophysiology of Nocturnal Scratching in Childhood Atopic Dermatitis: The Role of Brain-Derived Neurotrophic Factor and Substance P. Br J Dermatol, (2007). 157(5), 922-925.

24.. Toyoda, M, Nakamura, M, Makino, T, Hino, T, Kagoura, M, & Morohashi, M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol, (2002). 147(1), 71-79.

25.. Mosmann, TR, & Coffmann, RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol, (1989). 46, 111-139.

26.. Ogawa, H, Mukai, K, Kawano, Y, Minegishi, Y, & Karasuyama, H. Th2-inducing cytokines IL-4 and IL-33 synergistically elicit the expression of transmembrane TNF-α on macrophages through the autocrine action of IL-6. Biochem Biophys Res Commun, (2012). 420(1), 114-118.

27.. Werner, S, Krieg, T, & Smola, H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol, (2007). 127(5), 998-1008.

28.. Perkins, ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol, (2007). 8(1), 49-62.

29.. Bonizzi, G, & Karin, M. The two NF-κ B activation pathways and their role in innate and adaptive immunity. Trends Immunol, (2004). 25(6), 280-288.

30.. Monaco, C, Andreakos, E, Kiriakidis, S, Mauri, C, Bicknell, C, & Foxwell, B, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA, (2004). 101(15), 5634-5639.

31.. Arbabi, S, & Maier, RV. Mitogen-activated protein kinases. Crit Care Med, (2002). 30(1), S74-S79.

32.. Garrington, TP, & Johnson, GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol, (1999). 11(2), 211-218.

33.. Hong, ZY, Xiao, M, Yang, Y, Han, ZQ, Cao, Y, & Li, CR, et al. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation. Carcinogenesis, (2011). 32(10), 1550-1558.

34.. Liu, J, Lu, Y, Wu, Q, Goyer, RA, & Waalkes, MP. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther, (2008). 326, 363-368.

35.. Wester, RC, Hui, X, Barbadillo, S, Maibach, HI, Lowney, YW, & Schoof, RA, et al. In Vivo Percutaneous Absorption of Arsenic from Water and CCA-Treated Wood Residue. Toxicol Sci, (2004). 79(2), 287-295.